- Health & Pharmaceuticals›
- Pharmaceutical Products & Market›
Annual average cost of orphan drugs per patient 2014-2018
Industry-specific and extensively researched technical data (partially from exclusive partnerships).
A paid subscription is required for full access.
Annual average cost of orphan drugs per patient 2014-2018
Average annual cost of orphan drugs per patient from 2014 to 2018 (in U.S. dollars)*
This statistic displays the average cost per patient using orphan drugs per year in the U.S. from 2014 to 2018. In 2014, patients using orphan drugs accumulated average yearly costs of 128,063 U.S. dollars. Orphan drugs are used to target rare diseases or disorders, which in the United States is defined as less than 200,000 patients. The development of orphan drugs are currently incentivized in the United States through the Orphan Drug Act of 1983.
Average annual cost of orphan drugs per patient from 2014 to 2018 (in U.S. dollars)*
| Orphan | Non-orphan | |
|---|---|---|
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
| Orphan | Non-orphan | |
|---|---|---|
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
You need a Premium Account for unlimited access.
Full access to 1m statistics
Incl. source references
Available to download in PNG, PDF, XLS format
You need a Premium Account for unlimited access.
Full access to 1m statistics
Incl. source references
Available to download in PNG, PDF, XLS format
© Statista 2019
About this statistic
Show source
Please be patient - this may take a moment
Description
Source
More information
- Show sources information
- Show publisher information
- Release date
- April 2019
- Region
- United States
- Survey time period
- 2014 to 2018
- Supplementary notes
-
* Including the top 100 products.
* Products that have orphan and non-orphan drug designations and are expected to generate less than 50% of their sales in 2018 and 2024 from their orphan-designated indication/s, are excluded from this statistic. This has led to the exclusion of therapies such as Avastin, Opdivo, Enbrel, Herceptin, Humira and Remicade. - Open this statistic in...
Source
- Show sources information
- Show publisher information
- Release date
- April 2019
More information
- Region
- United States
- Survey time period
- 2014 to 2018
- Supplementary notes
-
* Including the top 100 products.
* Products that have orphan and non-orphan drug designations and are expected to generate less than 50% of their sales in 2018 and 2024 from their orphan-designated indication/s, are excluded from this statistic. This has led to the exclusion of therapies such as Avastin, Opdivo, Enbrel, Herceptin, Humira and Remicade. - Open this statistic in...
Other statistics on the topic
Orphan drugs
+Pharmaceutical Products & Market
Total global pharmaceutical R&D spending 2010-2024
+Pharmaceutical Products & Market
Top 50 pharmaceutical companies - Rx sales and R&D spending 2018
+Pharmaceutical Products & Market
Market share of top 20 companies for orphan drugs worldwide 2018 and 2024
Pharmaceutical Products & Market
Price comparison of the 10 most expensive drugs as of 2018
You only have access to basic statistics.
This statistic is not included in your account!
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$59 / Month *
Corporate solution including all features.
Prices do not include sales tax.
All Information
in one Presentation
- 56 page/s
- English
- pptx
- Detailed references
Everything On "Orphan drugs" in One Document: Edited and Divided into Handy Chapters. Including Detailed References.
I think of Statista as Google for researchers. Statista provides you with the information you search for right away.Dr. Horst Stipp
EVP, Research & Innovation, Advertising Research Foundation
- Market overview
- Global prescription orphan drug sales from 2010 to 2024 (in billion U.S. dollars)Projection of global revenue for orphan prescription drugs 2010-2024
- Global prescription orphan drug annual growth in revenues from 2011 to 2024Annual growth in global revenue for prescribed orphan drugs 2011-2024
- Average annual cost of orphan drugs per patient from 2014 to 2018 (in U.S. dollars)*Annual average cost of orphan drugs per patient 2014-2018
- Per-year list price of the top ten most expensive drugs worldwide as of 2018*Price comparison of the 10 most expensive drugs as of 2018
- Median cost per patient per year for orphan and non-orphan drugs from 2014 to 2018 (in U.S. dollars)Orphan vs. non-orphan drugs median cost per patient per year 2014-2018
- Companies
- Top 50 global pharmaceutical companies by prescription sales and R&D spending in 2018 (in billion U.S. dollars)Top 50 pharmaceutical companies - Rx sales and R&D spending 2018
- Top pharmaceutical companies by orphan drug revenue worldwide in 2018 (in billion U.S. dollars)Top global companies by orphan drug revenues 2018
- Forecast of top 10 pharmaceutical companies by global orphan drug revenue in 2024 (in billion U.S. dollars)*Top 10 companies by global revenue from orphan drugs 2024
- Top 20 pharmaceutical companies worldwide by orphan drug revenue market share in 2024 compared to 2018*Market share of top 20 companies for orphan drugs worldwide 2018 and 2024
- Products
- Top global orphan drugs by revenue in 2018 (in billion U.S. dollars)*Top global orphan drugs by revenue 2018
- Projected top 10 orphan drugs worldwide by revenue in 2024 (in billion U.S. dollars)*Projection of top 10 orphan drugs by global revenue 2024
- Annual number of accepted orphan designations in the United States from 2003 to 2018Number of orphan designations accepted in the U.S. 2003-2018
- Percentage of select orphan drugs' U.S. revenues attributable to non-orphan usage in 2017Percentage of select orphan drug US sales by non/orphan use 2017
- Percentage of FDA-approved orphan drugs with additional non-orphan indications between 1983 and 2018FDA approved orphan drugs with non-orphan indications 1983-2018
- Research and development
- Total global spending on pharmaceutical research and development from 2010 to 2024 (in billion U.S. dollars)Total global pharmaceutical R&D spending 2010-2024
- Projection of top 10 orphan drugs in development (phase III/filed) by NPV as of 2019 (in billion U.S. dollars)Leading orphan drugs in development based on net present value 2019
- Number of non-oncology orphan designated products currently being developed worldwide by company type as of April 2019Global therapeutic pipeline for non-oncology orphan drug programs by company 2019
- Average time from orphan drug designation to last remaining exclusivity in the U.S. as of 2018, by current statusTime from orphan drug design to final exclusivity 2018, by current status
- Probability of success for new rare disease and high prevalence disease drugs in the U.S. by development phase from 2006 to 2015U.S. development Phase success rates for rare and common disease drugs 2006-2015
- Rare diseases
- Number of rare diseases, disease patients and treatments worldwide and in the U.S. as of 2016Overview of rare diseases worldwide and in the U.S. as of 2016
- Life expectancy for individuals with select rare diseases before available treatment and now worldwide as of 2017Impact of medicines on life expectancy for select rare diseases worldwide as of 2017
- Distribution of patients in the U.S. with rare factor deficiencies as of 2019, by gender* Distribution of U.S. patients with rare factor deficiencies as of 2019, by gender
- Feelings of patients with rare diseases in the U.S. compared to other patients as of 2015U.S. rare disease patient feelings as of 2015
- Required number of patients for phase III trials of orphan and non-orphan drugs 2015
- Number of cumulative orphan designations accepted in the U.S. 2003-2018
- Median length of orphan and non-orphan drugs in phase III trial 2015
- Leading orphan drugs based on R&D phase III cost 2015
- Average FDA approved orphan drug sales U.S. 5 years after launch 2014
- Leading orphan designations in the EU by indication 2015
- Top new orphan molecular entities by U.S. sales in 2019
- Median length of time for orphan and non-orphan drugs for FDA approval 2015
- Orphan vs. non-orphan drugs median cost per patient per year 2014-2018
- Orphan vs. non-orphan pipeline sales forecast worldwide 2019-2024
- Impact of clinical trials on the daily lives of participants globally 2017
- Pricing of orphan drugs across three countries on annual basis 2016
- Patient reasons for participating in clinical trials globally as of 2017
- Clinical research study types that patients participated in worldwide 2017
- Drug spending in the U.S. 2013-2017, by specialty and orphan status
- Number of patients per rheumatologist by department in France 2014
- mHealth expectation to alter healthcare from patient opinion 2012
- Attitudes towards the services of medical appointment booking websites France 2016, by age
- Perception of the accessibility of the French health system 2016
- Number of inpatients in Chinese health institutions 2018, by region
- Projection of global revenue for orphan prescription drugs 2010-2024
- Annual growth in global revenue for prescribed orphan drugs 2011-2024
- Annual average cost of orphan drugs per patient 2014-2018
- Price comparison of the 10 most expensive drugs as of 2018
- Orphan vs. non-orphan drugs median cost per patient per year 2014-2018
- Total global pharmaceutical R&D spending 2010-2024
- Leading orphan drugs in development based on net present value 2019
- Global therapeutic pipeline for non-oncology orphan drug programs by company 2019
- Time from orphan drug design to final exclusivity 2018, by current status
- U.S. development Phase success rates for rare and common disease drugs 2006-2015
- Required number of patients for phase III trials of orphan and non-orphan drugs 2015
- Number of cumulative orphan designations accepted in the U.S. 2003-2018
- Median length of orphan and non-orphan drugs in phase III trial 2015
- Leading orphan drugs based on R&D phase III cost 2015
- Average FDA approved orphan drug sales U.S. 5 years after launch 2014
- Leading orphan designations in the EU by indication 2015
- Top new orphan molecular entities by U.S. sales in 2019
- Median length of time for orphan and non-orphan drugs for FDA approval 2015
- Orphan vs. non-orphan drugs median cost per patient per year 2014-2018
- Orphan vs. non-orphan pipeline sales forecast worldwide 2019-2024
- Impact of clinical trials on the daily lives of participants globally 2017
- Pricing of orphan drugs across three countries on annual basis 2016
- Patient reasons for participating in clinical trials globally as of 2017
- Clinical research study types that patients participated in worldwide 2017
- Drug spending in the U.S. 2013-2017, by specialty and orphan status
- Number of patients per rheumatologist by department in France 2014
- mHealth expectation to alter healthcare from patient opinion 2012
- Attitudes towards the services of medical appointment booking websites France 2016, by age
- Perception of the accessibility of the French health system 2016
- Number of inpatients in Chinese health institutions 2018, by region
Statista offers dossiers and reports on over 170 industries. With Statista you are always able to make informed decisions and boost your work efficiency.
- Social Media
- E-Commerce
- Online Video & Entertainment
- Advertising & Marketing
- Alcoholic Beverages
- Cleaning Products
- Cosmetics & Personal Care
- Food & Nutrition
- Health & Hygiene
- International Trade
- Shopping Behavior
- Sports & Leisure
- Business Travel
- Leisure Travel
- Accomodation
- Restaurants
- Demographics
- Economy
- Education & Science
- Politics & Government
- Aviation
- Rail Transport
- Vehicles & Road Traffic
- Water Transport
You can only download this statistic as a Premium user.
You can only download this statistic as a Premium user.
You can only download this statistic as a Premium user.
As a Premium user you get access to the detailed source references and background information about this statistic.
As a Premium user you get access to background information and details about the release of this statistic.
As soon as this statistic is updated, you will immediately be notified via e-mail.
...and make my research life easier.
You need at least a Premium Account to use this feature.
This feature is limited to our corporate solutions.
Please contact us to get started with full access to dossiers, forecasts, studies and international data.
We use cookies to personalize contents and ads, offer social media features, and analyze access to our website. In your browser settings you can configure or disable this, respectively, and can delete any already placed cookies. For details, please see your browser’s Help section (by pressing F1). Please see our privacy statement for details about how we use data.